Cwm LLC grew its stake in NxStage Medical, Inc. (NASDAQ:NXTM) by 10.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,149 shares of the medical device company’s stock after acquiring an additional 11,736 shares during the period. Cwm LLC owned 0.19% of NxStage Medical worth $2,984,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Athos Capital Ltd bought a new position in shares of NxStage Medical in the 3rd quarter valued at about $579,000. Sterling Capital Management LLC grew its holdings in shares of NxStage Medical by 26.6% in the 3rd quarter. Sterling Capital Management LLC now owns 81,767 shares of the medical device company’s stock valued at $2,257,000 after acquiring an additional 17,193 shares in the last quarter. California Public Employees Retirement System grew its holdings in shares of NxStage Medical by 11.7% in the 3rd quarter. California Public Employees Retirement System now owns 103,761 shares of the medical device company’s stock valued at $2,864,000 after acquiring an additional 10,861 shares in the last quarter. Highbridge Capital Management LLC bought a new position in shares of NxStage Medical in the 3rd quarter valued at about $4,140,000. Finally, Burren Capital Advisors Ltd bought a new position in shares of NxStage Medical in the 3rd quarter valued at about $806,000. Institutional investors own 85.35% of the company’s stock.
In related news, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $25.35, for a total transaction of $88,725.00. Following the completion of the transaction, the senior vice president now owns 14,270 shares in the company, valued at $361,744.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 10,500 shares of company stock valued at $275,030 in the last quarter. 4.70% of the stock is currently owned by corporate insiders.
Several brokerages have recently weighed in on NXTM. Zacks Investment Research cut NxStage Medical from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Canaccord Genuity restated a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a report on Tuesday, October 17th. Finally, Northland Securities restated a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating and nine have given a hold rating to the company’s stock. NxStage Medical has a consensus rating of “Hold” and an average price target of $30.25.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Week Herald and is owned by of Week Herald. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://weekherald.com/2018/01/18/cwm-llc-has-2-98-million-stake-in-nxstage-medical-inc-nxtm.html.
NxStage Medical Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.